Comparison of gastric pH with omeprazole magnesium 20.6 mg (Prilosec OTC) o.m. famotidine 10 mg (Pepcid AC) b.d. and famotidine 20 mg b.d. over 14 days of treatment-Reference-Cited by-同舟云学术

Comparison of gastric pH with omeprazole magnesium 20.6 mg (Prilosec OTC) o.m. famotidine 10 mg (Pepcid AC) b.d. and famotidine 20 mg b.d. over 14 days of treatment

Published:2006-12-06 Issue:1 Volume:25 Page:103-109
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:

Author:

MINER P. B.,ALLGOOD L. D.,GRENDER J. M.

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2036.2006.03129.x/fullpdf

Reference19 articles.

1. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study;Miner;Am J Gastroenterol,2003

2. Optimizing the pharmacology of acid control in acid-related disorder;Howden;Am J Gastroenterol,1997

3. The continuing development of gastric pump inhibitors;Sachs;Aliment Pharmacol Ther,1993

4. Optimizing the pharmacology of acid control in acid-related disorder;Howden;Am J Gastroenterol,1997

5. Review article: Gastric pH - the most relevant predictor of benefit in reflux disease;Armstrong;Aliment Pharmacol Ther,2004

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing and mitigating pH-mediated DDI risks in drug development – formulation approaches and clinical considerations;Drug Metabolism Reviews;2024-05-03

2. Systematic Review of Clinical Guidelines for the Treatment of Functional Dyspepsia;Bulletin of Science and Practice;2024-02-15

3. The effects of treating GERD on the outcomes of otitis media with effusion: A systematic review and meta-analysis;American Journal of Otolaryngology;2024-01

4. Compared to histamine-2 receptor antagonist, proton pump inhibitor induces stronger oral-to-gut microbial transmission and gut microbiome alterations: a randomised controlled trial;Gut;2023-11-22

5. Evaluation of the Efficacy and Safety of DW1903 in Patients with Gastritis: A Randomized, Double-Blind, Noninferiority, Multicenter, Phase 3 study;Gut and Liver;2023-06-13